Guangdong Zhongsheng Pharmaceutical (SHE:002317) said China's drug regulator accepted the new drug marketing application for anladwevir granule.
The drug is used to treat uncomplicated influenza A in children, according to a Thursday filing with the Shenzhen bourse.